Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Posted: February 25, 2025 at 2:45 am

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:

Read this article:
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Related Posts